Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 77771-124

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 77771-124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Radha Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of clopidogrel bisulfate showing the molecular framework including the thiophene ring, piperidine ring, chlorophenyl group, and associated ester and sulfate components.*

FDA Label Image

Figure1 (Clopidogrel Fig 1)

A horizontal dot plot showing the effect of co-administered proton pump inhibitors (PPIs) — Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg — on the active metabolite AUC of clopidogrel. The graph depicts mean values and 90% confidence intervals for change relative to clopidogrel administered alone, with a horizontal axis ranging from 0.4 to 1.4.*

FDA Label Image

Figure3 (Clopidogrel Fig 2)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two treatment groups are compared: placebo plus aspirin and clopidogrel plus aspirin. The graph indicates lower event rates for the clopidogrel plus aspirin group, with a p-value of 0.00009 indicating statistical significance.*

FDA Label Image

Figure3 (Clopidogrel Fig 3)

A forest plot chart depicting hazard ratios with 95% confidence intervals comparing Clopidogrel bisulfate (Clopidogrel) and placebo across various subgroups. The chart includes subgroups based on age, gender, race, history of cardiovascular events, diabetes status, prior myocardial infarction, stroke history, heparin/LMWH use, aspirin dosage, GP IIb/IIIa antagonist use, beta-blockers, and ACE inhibitors. Each subgroup shows the number of participants, events for Clopidogrel and placebo, and graphical hazard ratios indicating favor towards Clopidogrel or placebo.*

FDA Label Image

Figure4 (Clopidogrel Fig 4)

A survival curve chart showing the percentage of deaths before first discharge over 28 days since randomization. It compares placebo and Clopidogrel groups, indicating 1845 deaths (8.1%) for placebo and 1726 deaths (7.5%) for Clopidogrel, with a noted 7% proportional risk reduction (p=0.03). The y-axis represents percentage dead, and the x-axis shows days since randomization up to 28 days.*

FDA Label Image

Figure5 (Clopidogrel Fig 5)

A Kaplan-Meier curve chart showing the percentage of patients with death, re-infarction, or stroke before first discharge over time (up to 28 days) since randomization. The graph compares outcomes between placebo and clopidogrel groups, with the placebo group showing a higher event rate than the clopidogrel group, indicating a 9% proportional risk reduction (p=0.002) in the clopidogrel group.*

FDA Label Image

Figure6 (Clopidogrel Fig 6)

A forest plot displaying odds ratios with 99% confidence intervals for various subgroups comparing Clopidogrel bisulfate versus placebo. Subgroups include gender, age at entry, hours since onset, systolic blood pressure ranges, heart rate categories, and fibrinolytic agent use. The chart shows numeric counts and percentages for each group and indicates whether outcomes favor Clopidogrel or placebo across these subgroups.*

FDA Label Image

Figure7 (Clopidogrel Fig 7)

A line graph comparing the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up for aspirin and clopidogrel. The graph shows two curves, with clopidogrel having a slightly lower event rate than aspirin. The p-value is 0.045, indicating statistical analysis of the data.*

FDA Label Image

Figure8 (Clopidogrel Fig 8)

A hazard ratio forest plot comparing Clopidogrel and Aspirin across various conditions: Stroke, MI (Myocardial Infarction), and PAD (Peripheral Artery Disease). The plot displays event counts and percentages for both drugs alongside hazard ratios with 95% confidence intervals, showing a visual comparison of favorability toward either Clopidogrel or Aspirin for each condition and overall.*

FDA Label Image

75mg-30s (75mg 30s)

Label for Clopidogrel tablets USP, 75 mg, film-coated oral tablets. The label displays the drug name, strength (75 mg), and quantity (30 tablets) intended for prescription use only (Rx Only). It includes storage instructions, manufacturer information (ScieGen Pharmaceuticals, Inc.), and distributor details (Radha Pharmaceuticals, Inc.). The label also contains a barcode and instructs pharmacists to dispense the Medication Guide with each prescription.*

FDA Label Image

75mg-90s (75mg 90s)

Label for Clopidogrel bisulfate tablets, USP 75 mg, film-coated oral tablets. The label states 90 tablets per container and is marked Rx Only. Storage instructions are included, along with a note to dispense the Medication Guide. The label shows the NDC 77771-124-90 and lists Radha Pharmaceuticals, Inc. as the labeler and ScieGen Pharmaceuticals, Inc. as the manufacturer. A barcode and the words "NO VARNISH" are also visible.*

FDA Label Image

75mg-500s (75mg 500s)

Label for Clopidogrel tablets USP 75 mg by Radha Pharmaceuticals, Inc., containing 1,000 film-coated tablets. The label includes storage instructions, reference to a medication guide, and identifies the manufacturer as ScieGen Pharmaceuticals, Inc. Barcode and NDC 77771-124-10 are visible. The label also states 'NO VARNISH' on the right side.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.